ACT's Phase 1/2 Program for Retinal Degeneration
ACT has developed a human embryonic stem cell-based therapy that uses retinal pigment epithelial (RPE) cells to treat a variety of blindness-causing retinal degenerative diseases.
ACT's Phase 1/2 clinical program consists of two trials to assess the safety and tolerability of RPE cell therapy, one in patients with Stargardt's disease (juvenile macular degeneration) and the other in dry age-related macular degeneration (Dry AMD).
For more information on ACT's Phase 1/2 human clinical trial for Stargardt's Macular Dystrophy (SMD), click here.
For more information on ACT's Phase 1/2 human clinical trial for Dry Age-Related Macular Degeneration (Dry AMD), click here.